Medpace Q1 2026: Solid Growth Amidst Cancellations

Medpace Holdings reported Q1 2026 earnings with a 26.5% revenue increase to $706.6 million, but cancellations surged, dragging net bookings to $618.4 million and a book-to-bill ratio of 0.88. EBITDA rose 25.9% to $149.4 million, and net income grew 8.1% to $123.9 million, or $4.28 per share. Cancellations were mainly in oncology and cardiovascular due to product issues or reprioritizing, not funding problems. Guidance for the full year remains unchanged, and theyre hiring to boost pipeline and win rates. Despite tougher revenue paths, Medpaces focus on biotech clients and internal efficiencies keeps long-term trajectory upward. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/606ba05c5164229b